|
 Viral immunotherapy represents a new way of treating cancer by using
transgenes, or genes that are artificially introduced into the
genome of another organism. A number of companies are working to
harness the power of specific viruses to fight tumors using this
technology.
"AstraZeneca will select the transgenes to be encoded within the
virus and will be responsible for further in-vivo pre-clinical
development and, subject to option exercise, clinical development
and commercialization of these novel oncolytic immunotherapies,"
Transgene said.
AstraZeneca has been moving deeper into cancer therapy market
through wide-ranging deals, including those for immunotherapy and
targeted therapy.
[to top of second column] |
Last month, AstraZeneca agreed to a multi-billion dollar oncology
deal with Japan's Daiichi Sankyo Co Ltd, on a hotly-tipped
experimental treatment for breast cancer, in a direct challenge to
the world's biggest cancer drug maker Roche.
Transgene said it would receive $10 million upon signing and
additional pre-clinical success milestone payments of up to $3
million.
(Reporting by Justin George Varghese in Bengaluru; Editing by
Saumyadeb Chakrabarty)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
